Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Research Council grant · Running

SUITEX A completely biological and human tissue-engineered sling produced from Cell-Assembled extracellular Matrix (CAM) in vitro for the treatment of Stress Urinary Incontinence (SUI)

Coordinator
Institut National De La Sante Et De La Recherche Medicale, France
Runs
1 January 2025 to 30 June 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101189393

What the project is doing

In the project's own words, from its summary on CORDIS.

Stress Urinary Incontinence (SUI) is a major medical issue affecting 1 in 5 women. Implantation of synthetic slings, made of knitted plastic monofilament, is the gold standard surgical treatment. They provide mechanical support to the urethra avoiding involuntary loss of urine on effort. However, they are associated with serious complications and some countries have already suspended their use. Hence, there is a strong medical and societal need for breakthrough innovations.

The two fundamental problems of synthetic slings are the excessive hardness of the material and the foreign body reaction it creates. We propose a new paradigm by providing a non-living tissue-engineered sling that is soft, yet strong, as well as completely biological and human. Our strategy is based on a unique material: the Cell-Assembled extracellular Matrix (CAM) produced by fibroblasts in vitro. We can produce robust CAM sheets from human or ovine cells with similar properties.

They are cut to produce threads subsequently woven into CAM slings. The potential of CAM slings to treat SUI will be demonstrated through 2 main tasks:1) Development of human and ovine CAM slings with mechanical properties justifying a preclinical study.2) In vivo validation of allogenic CAM slings in a female sheep model at 2 and 6 months. This PoC will:1) Prove that human CAM slings can have clinically relevant mechanical properties;2) Demonstrate that equivalent ovine CAM slings can be successfully implanted in a clinically relevant, allogenic, large animal model;3) Show a superior integration of ovine CAM slings compared to synthetic slings (reduced immune response and positive remodeling).

Overall, this PoC will increase the technology readiness level of our product from 1-2 to 3-4. These outcomes will justify an expanded in vivo analysis and support a commercial endeavor targeting clinical application.

Who is involved

OrganisationCityCountryRole
Institut National De La Sante Et De La Recherche MedicaleParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI